XML 55 R45.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Development, Commercialization and Supply Agreement - Additional Information (Detail) | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
Sep. 30, 2017 USD ($) | Mar. 31, 2016 USD ($) | Feb. 28, 2015 USD ($) | Mar. 31, 2018 USD ($) Item | Mar. 31, 2017 USD ($) | Dec. 31, 2017 USD ($)
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Licensing revenue |  |  |  | $ 142,000 | $ 293,000 |
Deferred revenue |  |  |  | $ 18,912,000 |  | $ 19,054,000
Eddingpharm |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Non-refundable up-front received |  |  | $ 15,000,000 |  |  |
Number of indications of the regulatory milestone events relating to the submission and approval | Item |  |  |  | 3 |  |
Amounts to be received upon achievement of the regulatory milestone events |  |  |  | $ 33,000,000 |  |
Sales-based milestone event payment |  |  |  | 120,000,000 |  |
Licensing revenue |  |  |  |  | 300,000 |
Licenses revenue to date |  |  |  | 2,800,000 |  | 3,100,000
Deferred revenue |  |  |  | $ 13,200,000 | 12,900,000 |
Revenue recognized over remaining period |  |  |  | 16 years |  |
Eddingpharm | Maximum |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone |  |  |  | $ 153,000,000 |  |
Amounts to be received upon achievement of the regulatory milestone events |  |  |  | 15,000,000 |  |
Sales-based milestone event payment |  |  |  | 50,000,000 |  |
Licensing revenue |  |  |  | 100,000 |  |
Eddingpharm | Minimum |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Amounts to be received upon achievement of the regulatory milestone events |  |  |  | 1,000,000 |  |
Sales-based milestone event payment |  |  |  | 5,000,000 |  |
Eddingpharm | Clinical Trial Application |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Non-refundable milestone payment |  | $ 1,000,000 |  |  |  |
Biologix FZCo |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Revenue recognition period of non-refundable up-front payment |  | 10 years |  |  |  |
HLS |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Non-refundable up-front received | $ 5,000,000 |  |  |  |  |
Licensing revenue |  |  |  | 100,000 | $ 0 |
Licenses revenue to date |  |  |  | 300,000 |  | 100,000
Deferred revenue |  |  |  | $ 4,700 |  | $ 4,900
Revenue recognized over remaining period |  |  |  | 12 years |  |
Non-refundable up-front received period | 6 months |  |  |  |  |
HLS | Maximum |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone | $ 60,000,000 |  |  |  |  |

X
- Definition Estimated number of days following the end of the quarter before related revenue is recognized. + References No definition available. + Details
Name: | amrn_DeferredRevenueRecognitionPeriod
Namespace Prefix: | amrn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Eligible milestone payment. + References No definition available. + Details
Name: | amrn_EligibleMilestonePayment
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Eligible regulatory milestone event payment. + References No definition available. + Details
Name: | amrn_EligibleRegulatoryMilestoneEventPayment
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Eligible sales based milestone event payment. + References No definition available. + Details
Name: | amrn_EligibleSalesBasedMilestoneEventPayment
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License And Collaboration Agreements [Line Items] + References No definition available. + Details
Name: | amrn_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | amrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Licenses revenue to date. + References No definition available. + Details
Name: | amrn_LicensesRevenueToDate
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Non refundable upfront payments received. + References No definition available. + Details
Name: | amrn_NonRefundableUpfrontPaymentsReceived
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable upfront payments received period. + References No definition available. + Details
Name: | amrn_NonRefundableUpfrontPaymentsReceivedPeriod
Namespace Prefix: | amrn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Nonrefundable milestone payment. + References No definition available. + Details
Name: | amrn_NonrefundableMilestonePayment
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of regulatory milestone events indications. + References No definition available. + Details
Name: | amrn_NumberOfRegulatoryMilestoneEventsIndications
Namespace Prefix: | amrn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130556-203045 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=84173487&loc=SL51747714-108306 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_EddingpharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=amrn_ClinicalTrialApplicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_BiologixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_HLSTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |